# David Fellows

> David Fellows is Beacon Therapeutics’ non-executive chairman and founding CEO. His career includes 25 years at Allergan, leadership of global marketing, new products and licensing at Johnson & Johnson, and taking Nightstar Therapeutics through a Nasdaq listing and its acquisition by Biogen. He holds a B.A. in Psychology from Butler University and is based in Ponte Vedra Beach, Florida.

- **Role:** Non-Executive Chairman at Beacon Therapeutics
- **Organizations:** Beacon Therapeutics, Nightstar Therapeutics, Johnson & Johnson, Allergan, Oxular, Jaguar Gene Therapy, The Glaucoma Foundation, Terns Pharmaceuticals
- **Education:** B.A. in Psychology, Butler University
- **Known for:** Led Nightstar through its Nasdaq listing and acquisition by Biogen., Oversaw the launch of Beacon Therapeutics in June 2023., Oversaw Beacon’s $170 million Series B closing in July 2024.

## Career timeline

- **Before 2005** — Spent 25 years at Allergan in sales, marketing and leadership roles across North America, Europe and Asia, including regional president.
- **2005-2014** — Vice President of Johnson & Johnson’s Vision Care Franchise; led global marketing, new product and licensing activities.
- **2015-01** — Appointed CEO of Nightstar Therapeutics.
- **2017-09** — Rang Nasdaq’s closing bell to celebrate Nightstar’s IPO.
- **2017-10** — Nightstar closed its IPO, receiving approximately $77.4 million in net proceeds.
- **2019-06** — Biogen completed the acquisition of Nightstar for approximately $800 million after expected transaction expenses and cash at closing.
- **2020-12** — Joined the Terns Pharmaceuticals board.
- **2021-02** — Became chairman of Terns Pharmaceuticals.
- **2022-11** — Became CEO following Syncona’s acquisition of AGTC.
- **2023-06** — Oversaw Beacon Therapeutics’ launch with £96 million, approximately $120 million, in Series A financing.
- **2024-07** — Oversaw closing of Beacon’s $170 million Series B; company announced CEO succession.
- **2025-01** — Became Beacon’s non-executive chairman according to Beacon’s current biography and succession announcement.

## Achievements

- Led Nightstar through its Nasdaq listing and acquisition by Biogen.
- Oversaw the launch of Beacon Therapeutics in June 2023.
- Oversaw Beacon’s $170 million Series B closing in July 2024.

## Latest updates

- **2025-01** — Transitioned to non-executive chairman of Beacon; the current company leadership page continues to list him as chairman.

## Links

- LinkedIn: https://www.linkedin.com/in/david-fellows-94876526

---

Profile page: https://yespress.io/david-fellows
Published by YesPress — https://yespress.io
Last updated: 2026-10-12